Literature DB >> 25944535

Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis.

Giovanni Piccaro1, Giovanna Poce2, Mariangela Biava2, Federico Giannoni1, Lanfranco Fattorini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25944535     DOI： 10.1038/ja.2015.52

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  23 in total

1.  Effect of meropenem against multidrug-resistant Mycobacterium tuberculosis.

Authors:  A Y Coban; K Bilgin; N Tasdelen Fisgin; M Uzun; B Durupinar
Journal:  J Chemother       Date:  2008-06       Impact factor: 1.714

2.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

Review 3.  Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?

Authors:  Robert C Goldman
Journal:  Tuberculosis (Edinb)       Date:  2013-09-18       Impact factor: 3.131

Review 4.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.

Authors:  Sean Ekins; Joel S Freundlich; Inhee Choi; Malabika Sarker; Carolyn Talcott
Journal:  Trends Microbiol       Date:  2010-12-02       Impact factor: 17.079

5.  Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.

Authors:  Rokeya Tasneen; Kathy Williams; Opokua Amoabeng; Austin Minkowski; Khisimuzi E Mdluli; Anna M Upton; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

Review 6.  The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells.

Authors:  Véronique Dartois
Journal:  Nat Rev Microbiol       Date:  2014-02-03       Impact factor: 60.633

Review 7.  Predicting natural product value, an exploration of anti-TB drug space.

Authors:  Yousef Dashti; Tanja Grkovic; Ronald J Quinn
Journal:  Nat Prod Rep       Date:  2014-08       Impact factor: 13.423

8.  Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection.

Authors:  Giovanna Poce; Robert H Bates; Salvatore Alfonso; Martina Cocozza; Giulio Cesare Porretta; Lluís Ballell; Joaquin Rullas; Fátima Ortega; Alessandro De Logu; Emanuela Agus; Valentina La Rosa; Maria Rosalia Pasca; Edda De Rossi; Baojie Wae; Scott G Franzblau; Fabrizio Manetti; Maurizio Botta; Mariangela Biava
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

9.  Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents.

Authors:  Suresh B Lakshminarayana; Tan Bee Huat; Paul C Ho; Ujjini H Manjunatha; Véronique Dartois; Thomas Dick; Srinivasa P S Rao
Journal:  J Antimicrob Chemother       Date:  2014-11-11       Impact factor: 5.758

10.  Non-replicating Mycobacterium tuberculosis elicits a reduced infectivity profile with corresponding modifications to the cell wall and extracellular matrix.

Authors:  Joanna Bacon; Luke J Alderwick; Jon A Allnutt; Evelina Gabasova; Robert Watson; Kim A Hatch; Simon O Clark; Rose E Jeeves; Alice Marriott; Emma Rayner; Howard Tolley; Geoff Pearson; Graham Hall; Gurdyal S Besra; Lorenz Wernisch; Ann Williams; Philip D Marsh
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240
View more
  15 in total

1.  Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.

Authors:  Angelo Iacobino; Giovanni Piccaro; Federico Giannoni; Alessandro Mustazzolu; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

2.  Alkaloids of Dicranostigma franchetianum (Papaveraceae) and Berberine Derivatives as a New Class of Antimycobacterial Agents.

Authors:  Viriyanata Wijaya; Ondřej Janďourek; Jana Křoustková; Kateřina Hradiská-Breiterová; Jan Korábečný; Kateřina Sobolová; Eliška Kohelová; Anna Hošťálková; Klára Konečná; Marcela Šafratová; Rudolf Vrabec; Jiří Kuneš; Lubomír Opletal; Jakub Chlebek; Lucie Cahlíková
Journal:  Biomolecules       Date:  2022-06-17

3.  Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility.

Authors:  Chee Wei Ang; Lendl Tan; Melissa L Sykes; Neda AbuGharbiyeh; Anjan Debnath; Janet C Reid; Nicholas P West; Vicky M Avery; Matthew A Cooper; Mark A T Blaskovich
Journal:  J Med Chem       Date:  2020-11-05       Impact factor: 7.446

4.  Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis.

Authors:  Giovanna Poce; Sara Consalvi; Giulia Venditti; Salvatore Alfonso; Nicoletta Desideri; Raquel Fernandez-Menendez; Robert H Bates; Lluis Ballell; David Barros Aguirre; Joaquin Rullas; Alessandro De Logu; Michelle Gardner; Thomas R Ioerger; Eric J Rubin; Mariangela Biava
Journal:  ACS Med Chem Lett       Date:  2019-09-18       Impact factor: 4.345

5.  Facile synthesis and antimycobacterial activity of isoniazid, pyrazinamide and ciprofloxacin derivatives.

Authors:  Shahinda S R Alsayed; Shichun Lun; Alan Payne; William R Bishai; Hendra Gunosewoyo
Journal:  Chem Biol Drug Des       Date:  2021-03-16       Impact factor: 2.873

6.  Hypoxic Non-replicating Persistent Mycobacterium tuberculosis Develops Thickened Outer Layer That Helps in Restricting Rifampicin Entry.

Authors:  Kishor Jakkala; Parthasarathi Ajitkumar
Journal:  Front Microbiol       Date:  2019-10-11       Impact factor: 5.640

7.  Initial In Vivo Evaluation of a Novel Amikacin-Deoxycholate Hydrophobic Salt Delivers New Insights on Amikacin Partition in Blood and Tissues.

Authors:  Styliani Xiroudaki; Federica Ianni; Samuele Sabbatini; Elena Roselletti; Claudia Monari; Roccaldo Sardella; Anna Vecchiarelli; Stefano Giovagnoli
Journal:  Pharmaceutics       Date:  2021-01-10       Impact factor: 6.321

8.  Easy-To-Access Quinolone Derivatives Exhibiting Antibacterial and Anti-Parasitic Activities.

Authors:  Richard M Beteck; Audrey Jordaan; Ronnett Seldon; Dustin Laming; Heinrich C Hoppe; Digby F Warner; Setshaba D Khanye
Journal:  Molecules       Date:  2021-02-20       Impact factor: 4.411

Review 9.  Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis.

Authors:  Diana Machado; Miriam Girardini; Miguel Viveiros; Marco Pieroni
Journal:  Front Microbiol       Date:  2018-07-03       Impact factor: 5.640

10.  A rapid, low pH, nutrient stress, assay to determine the bactericidal activity of compounds against non-replicating Mycobacterium tuberculosis.

Authors:  Julie V Early; Steven Mullen; Tanya Parish
Journal:  PLoS One       Date:  2019-10-07       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.